Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Therapeutics to Present at BIO CEO & Investor Conference on February 13, 2017
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 19 th
View HTML
Toggle Summary Mateon Therapeutics to Present Data on Study OX4218 in Neuroendocrine Tumors at ASCO Gastrointestinal Cancers Symposium
- Data Shows Additional Evidence of CA4P Activity - - Investigator-sponsored Study Initiating, Based on OX4218 Results - SOUTH SAN FRANCISCO, Calif. , Jan. 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs)
View HTML
Toggle Summary Mateon Common Stock to Trade on OTCQX Beginning on December 8, 2016
SOUTH SAN FRANCISCO, Calif. , Dec. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that shares of its common stock will be eligible for
View HTML
Toggle Summary Mateon Announces Presentation of OXi4503 AML Study Data at 58th Annual Meeting of American Society of Hematology
- Completed enrollment in the two lowest dose cohorts, third cohort now in progress - - Patients had on average failed 4 prior therapies - - Across the first two cohorts, 20% of patients achieved a complete remission - SOUTH SAN FRANCISCO, Calif. , Dec.
View HTML
Toggle Summary Mateon Provides Corporate Update and Reports Third Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for
View HTML
Toggle Summary Mateon Announces Adjournment of Special Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the special meeting of stockholders scheduled for
View HTML
Toggle Summary Mateon Announces Presentation of CA4P Posters at Meeting of the International Gynecologic Cancer Society
- Patients with Measurable Disease Showed Significantly Improved Progression-Free Survival - - Progression-Free Survival Improved by 6.2 Months for Patients with Larger Tumors - SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc .
View HTML
Toggle Summary Mateon Expands Board of Directors with the Appointments of Donald R. Reynolds and Bobby W. Sandage, Jr., Ph.D.
SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced the appointment of two new members to its board of
View HTML
Toggle Summary Mateon Announces Issuance of US Patent for Cathepsin Inhibition
SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S.
View HTML
Toggle Summary Mateon Announces Collaboration with US Oncology Research to Participate in Phase 2/3 FOCUS Study
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced a collaboration under which sites affiliated with US
View HTML